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Available online 14 October 2016Immunization in pregnancy provides a promising contribution to globally reducing neonatal and under-
five childhood mortality and morbidity. Thorough assessment of benefits and risks for the primarily
healthy pregnant women and their unborn babies is required. The GAIA project was formed in response
to the call of the World Health Organization for a globally concerted approach to actively monitor the
safety of vaccines and immunization in pregnancy programs. GAIA aims to improve the quality of out-
come data from clinical vaccine trials in pregnant women with a specific focus on the needs and require-
ments for safety monitoring in LMIC.
In the first year of the project, a large and functional network of experts was created. The first outputs
include a guidance document for clinical trials of immunization in pregnancy, a basic data collection
guide, ten case definitions of key obstetric and neonatal health outcomes, an ontology of key terms
and a map of pertinent disease codes.
The GAIA Network is designed as an open and growing forum for professionals sharing the GAIA vision
and aim. Based on the initial achievements, tools and services are developed to support investigators and
strengthen immunization in pregnancy programs with specific focus on LMIC.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).1. Introduction
Reducing neonatal and under-five childhood mortality and
morbidity is a target of the Health Sustainable Development Goal
[1]. Immunization in pregnancy provides a promising contributionto achieving this goal [2]. Whilst immunizing pregnant women
against tetanus has been practiced for decades, new strategies such
as antenatal influenza and pertussis vaccination are now being sys-
tematically evaluated and are recommended by WHO [3–5]. Addi-
tional promising vaccines are in development for global use in
pregnancy such as group B streptococcal (GBS) and respiratory
syncytial virus (RSV) vaccines [6–8].
Introduction of these vaccines comes with tremendous poten-
tial benefit, specifically for women and children living in low and
middle income countries (LMIC) due to the higher perinatal and
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stake when it comes to immunization of pregnant women. The
safety of any product given to primarily healthy mothers and their
unborn babies receives intense professional and public scrutiny.
First, this is because two lives can be directly affected during a time
of vulnerability, yet both are also likely to benefit from the preven-
tion of serious infections Second, safety concerns are not exclusive
to maternal vaccination programs alone since similar concerns are
raised with the use of the same vaccines in routine childhood and
adult immunization programs (e.g., influenza and pertussis vacci-
nes). In turn, a vaccine found to be safe for pregnant women and
neonates would likely be well accepted by the general public for
other target groups. Thus, the potential beneficial and harmful
effects of immunization in pregnancy and its ethical implications
are augmented by the ramifications on routine pediatric and adult
immunization programs. Therefore, thorough assessment of the
safety of vaccines during pregnancy is required given the potential
for numerous confounding events associated with pregnancy itself
in women and the fetus, and in the neonatal period.
Particularly challenging for monitoring and communicating the
benefits and risks of immunization programs in pregnancy is that
several common health outcomes may be perceived as both a mea-
sure of benefit and risk and this assessment may change over time.
For example, immunizationmay decrease the stillbirth rate if a vac-
cine decreases infections that lead to stillbirth. However, stillbirths
will still occur in pregnancies and may also be perceived and
reported as adverse events following immunization. Particularly
early during program introduction, the impact of reducingmortality
due to immunizationmay not be detectable on the population level
while pregnancy complications, such as stillbirth, are registered.
Thismakes early benefit-risk analyses challenging andmay compro-
mise the viability of an immunizationprogram independently of any
causal relationship between the complication and immunization.
Therefore, product or program specific safety issues need to be
identified to appropriately assess the benefit-risk profile of these
vaccines and their implementation programs and to protect the
target population from unintended harm. On the other hand,
unfounded public or professional concerns can jeopardize
beneficial vaccine programs and need to be rapidly refuted based
on rigorous and credible science and globally coordinated
decision-making and communication.
Addressing these issues requires more than communication
strategies. It requires active monitoring and research to enable
confident communication with high quality data. As important
safety concerns tend to be serious but rare health events, their
investigation requires a harmonized approach and needs to be
based on large sample sizes to provide satisfactory statistical con-
fidence of risk estimates and to enable comparison of multiple
populations and programs. This is best addressed by close global
collaboration based on a harmonized approach [9–11].
The general need for a globally concerted approach to actively
monitor the safety of vaccines and programs of immunization is
recognized by the WHO Global Vaccine Safety Blueprint, the
strategic plan of the Global Vaccine Safety Initiative [12]. A recent
WHO consultation specifically identified the currently fragmented
research, the current lack of data comparability as well as the need
to improve the quality of safety data to inform decision making
and system strengthening [13].2. The GAIA project
2.1. Aim and objectives and first outcomes
The GAIA project aims to improve the outcome data quality
from clinical vaccine trials in pregnant women with a specific focuson the needs and requirements for safety monitoring in LMIC. GAIA
addresses three main objectives to achieving this aim. First, to
improve comparability of safety data across products, programs,
and populations for effective and efficient strengthening of immu-
nization programs in pregnant women. Second, to optimize the
value of local investigations by global harmonization of methods.
Third, to promote scientific progress by increasing analytic power
and options through globally concerted approaches.
In a first step, the GAIA project has established an open and
dynamic network of professionals concerned with monitoring the
safety of immunization in pregnancy. Together, compiling a shared
terminology and developing case definitions for selected obstetric
and neonatal outcomes create a common understanding of the out-
comes monitored. Consensus guidance is developed for harmo-
nized safety monitoring in clinical trials, and tools are created for
effective and efficient data collection, synthesis and pooling, with
a focus on LMIC needs and requirements.
2.2. Network
The development of a global standard requires the engagement
of a large number of stakeholders (e.g. regulatory agencies, public
health organizations, academic institutions and health care provi-
ders) and experts who will collaborate on a voluntary basis on
the development, review and validation of the standards and tools
through an iterative process in the framework of multiple stream-
lined working groups with a specified task. The GAIA Network is
designed as an open and growing forum for professionals sharing
the GAIA vision and aim. In the first year of the project (January
to December 2015), the forum of partners, participants and stake-
holders has grown to 412 individual professionals. This was
achieved by identifying and inviting professionals active in the
field and calling for participation via pertinent professional organi-
zations and mailing lists. Table 1 shows their country of origin and
the distribution across WHO regions.
The formation and coordination of the network and the creation
and guidance of the working groups and activities requires a
dedicated small group of partners driving progress. In the GAIA
project, experts from 13 organizations (The US National Institutes
of Health, Brighton Collaboration Foundation, World Health
Organization, Global Healthcare Consulting, University of Wash-
ington, Baylor College of Medicine, Hudson Institute of Medical
Research, Erasmus Medical Center, Cincinnati Children’s Hospital,
St George’s, University of London, Public Health Agency Canada,
Synapse Research Management Partners and International Alliance
for Biological Standardization) collaborate in a carefully designed
governance structure to coordinate and guide the activities of the
network partners [14].
The GAIA project leverages the unique accrual of expertise in its
project partners and the wider network and is designed to achieve
its aim by capitalizing on existing methods and infrastructures. In
the following sections, we outline the methods and first outcomes
of the GAIA project.
2.3. Standardized case definitions for key outcomes
WHO and the Brighton Collaboration (BC) held a consultancy of
key stakeholders in July 24–25, 2014 in Geneva to review current
practice and advice on a strategic direction towards a harmonized
approach for monitoring immunization in pregnancy programs
[13]. This meeting highlighted the current lack of harmonization
and the missed opportunity of giving added value to individual
studies by overcoming fragmented research and diverse
approaches through consensus formation and harmonization. For
example, there is limited consensus and harmonization across
studies and analyses on even the most fundamental terms and
Table 1
GAIA Network by World Health Organization region and country.
AFRO 31 (7.5%) EURO 79 (19%)
South Africa 8 UK 17
Uganda 5 Netherlands 9
Burkina Faso 2 Sweden 7
Congo DR 2 Denmark 5
The Gambia 2 Germany 5
Ghana 2 Italy 5
Kenya 2 Spain 5
Burundi 1 United Kingdom 4
Cameroon 1 Greece 3
Ethiopia 1 Switzerland 3
Lebanon 1 France 2
Moçambique 1 Hungary 2
Nigeria 1 Latvia 2
Sudan 1 Albania 1
Togo 1 Austria 1
EMRO 4 (1%) Belgium 1
Egypt 1 Croatia 1
Iran 1 Poland 1
Morocco 1 Israel 1
United Arab Emirates 1 Portugal 1
PAHO 173 (41%) Russia 1
USA 131 Serbia 1
Uruguay 1 Slovenia 1
Colombia 1 WPRO 23(6%)
Canada 27 Taiwan 1
Brazil 7 Philippines 4
Bolivia 1 New Zealand 2
Argentina 5 Lao 1
SEARO 38 (9%) Korea Rep. 1
India 26 Japan 1
Pakistan 5 Cambodia 1
Bangladesh 2 Australia 12
Sri Lanka 1 INTa 64 (15%)
Nepal 1 Int. Organizations 64
Indonesia 1
Bhutan 1
Thailand 1
a This category is not a WHO Region, but comprises organizations with primarily
international or global scope (e. g. international vaccine manufacturers, public
health organizations).
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age [15]. Such differences can significantly impact interpretation
and meaningful data comparisons.
The GAIA consortium is developing standardized case defini-
tions of key outcomes according to the Brighton Collaboration
standard process [16]. Case definition development is prioritized
based on the recommendations of the global consultative process
held at the World Health Organization in 2014 and by the ad hoc
need for monitoring emerging safety concerns [17]. To achieve
the need of developing many definitions in a short timeframe,
the Brighton Collaboration standard process was expanded to
enable ‘‘batch production” of definitions. Two task forces compris-
ing expertise from public health institutes, regulatory authorities,Table 2
Standardized case definitions developed for the first 21 obstetric and neonatal outcomes.
Obstetric outcomes
First set of 10 case definitions  Hypertensive disorders of pregnancy
 Non-reassuring fetal status
 Postpartum hemorrhage
 Pathways to premature birth
 Maternal death
Second set of 10 case definitions  Abortion
 Antenatal bleeding
 Gestational diabetes
 Dysfunctional labor
 Intra uterine growth retardation
Additional case definitionacademic and patient care organizations and vaccine manufactur-
ers were created, to simultaneously develop ten neonatal and ten
obstetric outcome definitions, respectively, in dedicated working
groups. These groups are primarily comprised of neonatologists
and/or obstetricians while a few coordinating and advising profes-
sionals contribute vaccine safety expertise and guided the groups
on the Brighton Collaboration standard method of case definition
development. Case definitions are developed specifically to incor-
porate clinical assessment methods commonly used in LMIC to
optimize inclusion of cases from all settings. The draft case defini-
tions are developed based on literature review and consensus for-
mation within the respective working groups. These documents
are submitted for peer review by a reference group comprising
the GAIA Network of professionals concerned with immunization
in pregnancy, the Brighton Collaboration Network of professionals
concerned with vaccine safety and additional organizations or pro-
fessional societies with expertise in the respective outcome. Over-
all case definition development was coordinated by Global Health
Consulting, the neonatal task force by Baylor College of Medicine
and the obstetric task Force by University of Washington. Together
with the other partners in the Coordination Team, they were guid-
ing the simultaneous activities of over 200 volunteering profes-
sionals in the ten working groups, each led by a subject matter
expert driving the respective manuscript development. The first
10 case definitions (Table 2) establishing the proof of principle of
this modified approach are published in this special issue of Vac-
cine [18–27]. A subsequent set of 10 prioritized case definitions
is in development (Table 2). Demonstrating the flexibility, effi-
ciency and effectiveness of this established process, an additional
working group was formed to develop a case definition of micro-
cephaly on fast track in response to the Zika virus epidemic and
in preparation of related vaccine development efforts.
2.4. Guidelines and data collection matrix
The WHO and the Brighton Collaboration (BC) consultancy also
recognized the need for guidance on basic data collection, analysis
and presentation of vaccine safety data. This is specifically, because
no such global consensus guidelines exist to meet the need of con-
certed safety monitoring throughout the life cycle of vaccines or for
global access in rapidly emerging immunization in pregnancy
programs.
The GAIA project develops guidelines for harmonized data col-
lection, analysis and presentation according to the Brighton Collab-
oration standard process [16]. Based on existing Brighton
Collaboration guidance documents, St George’s, University of Lon-
don coordinated the development of the first GAIA guideline on
vaccine safety monitoring in clinical trials, which was finalized fol-
lowing wide peer review and feedback from investigators of ongo-
ing studies and parallel projects. It is published in this special issue
of Vaccine [28].Neonatal outcomes Enabling terms
 Stillbirth
 Preterm birth
 Congenital anomalies
 Neonatal infections
 Neonatal death
 Assessment of Gestational Age
 Live birth
 Low birth weight
 Small for gestational age
 Neonatal encephalopathy
 Respiratory distress in the newborn
 Failure to thrive
 Microcephaly
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ment of a data collection matrix outlining key variables to be col-
lected in different safety monitoring settings during the vaccine
and program life cycle. Based on the review of case report forms
(CRF) from previous immunization in pregnancy trials and the
new case definitions and guidance document a tailored subset
was compiled to facilitate harmonized collection of data in CRFs
in clinical vaccine trials involving pregnant women where safety
is an outcome. It was finalized following wide peer review and
feedback from investigators of ongoing studies and parallel pro-
jects and is also published in this special issue of Vaccine [29].2.5. Tools
To further promote a common understanding and shared lan-
guage, a list of over 3000 terms comprising obstetric and neonatal
outcomes (e.g. stillbirth) and enabling terms (e.g. prematurity) is
structured in an ontology catalog demonstrating their hierarchical
and conceptual dependencies enriched by synonyms and disease
concept descriptions. This is of particular use for the development
of multilingual data collection forms. This effort builds on the
existing products and expertise at the Enterprise Vocabulary Ser-
vices at the National Cancer Institute also in collaboration with
the National Children’s Study and the Eunice Kennedy Shriver
National Institute of Child Health and Human Development at
NIH and will be made available as an dedicated, user friendly,
searchable database on the NIH website.
The case definitions with the glossary and ontology of terms
have enabled creation of a map of disease codes that can be used
for retrieval of data on specific outcomes from electronic health
care databases (e.g., ICD9, ICD10, MedDRA, WHOArt, and READ).
The mapped disease codes will be made available via the same
GAIA terminology database described above. A systematic litera-
ture search on existing observational studies around pertussis
and influenza maternal immunization safety was coordinated by
Erasmus Medical Center and will reflect disease codes and algo-
rithms that have been used to extract data from electronic health
care databases and prepares for further expansion of the GAIA
work into observational settings.
The existing Automated Brighton Collaboration Case Classifica-
tion tool (ABC tool) will be expanded to include the newly devel-
oped set of case definitions for automated classification of
reported events into their level of diagnostic certainty. The rule
based tool classifies the information and also prompts the investi-
gator to the type of information that should be collected (on
follow-up) for a given case to meet the highest possible level of
diagnostic certainty [30]. All tools will be described in more detail
in an upcoming special issue of Vaccine.3. Dissemination
The GAIA project aims to serve different stakeholders in the field
of immunization in pregnancy. To achieve this aim, GAIA is promot-
ing review, use and recommendation of its outcomes by key
stakeholders in the field of global vaccine safety research and mon-
itoring including national and international public health and regu-
latory organizations aswell as vaccinemanufacturers. Similarly, the
wider scientific community and health care professionals are
invited to review outcomes early in the process, provide comments
and utilize the shared network, standards and tools. This effort is
facilitated by engagement and dialogue with stakeholder organiza-
tions, presentations and workshops at scientific conferences,
regular newsletters and publication in the scientific literature.
All outputs are made available through the GAIA website [31].
Immunization in pregnancy is an evolving field, and adaptationof standards and tools to specific vaccines, protocols, populations,
geographic regions, and other factors is necessary when evaluating
the safety of vaccines in pregnancy. The Brighton Collaboration is
addressing this continuing need and makes available an inven-
tory of GAIA standards and related work as part of its online
vaccine safety resources for professionals concerned with vaccine
safety [32].
Standards and tools should ultimately be applied in clinical tri-
als as well as in signal verification and hypothesis testing studies
and enable and accelerate multinational collaborative research
on immunization in pregnancy. To this end, GAIA inspired an Inter-
national Consensus Conference on Harmonized Safety Monitoring
of Immunization in Pregnancy in March 2016 at the National Insti-
tute of Health (NIH) in Bethesda, MD, U. S. A. The conference
brought together 142 registered participants from regulatory
authorities, public health institutes, academia and industry to dis-
cuss new safety data from immunization in pregnancy studies, to
identify converging stakeholder needs and requirements for high
quality data, to review GAIA standards and tools for safety moni-
toring and to build consensus on the best practice guidance for
monitoring vaccine safety in pregnancy in the light of current
experience with a focus on LMIC.3.1. Summary and next steps
The GAIA project has established a large and functional network
of experts and a purpose infrastructure around first outputs, which
may serve as a platform for continued collaborative improvement
of the quality of data generated for strengthening programs of
immunization in pregnancy with specific focus on LMIC. The
immediate next outputs will be the next set of eleven case defini-
tions and the finalized online services and tools.
Capitalizing on the initial achievements of the GAIA project and
following the recommendations of the consensus conference, GAIA
could also be effectively utilized as a platform for capacity building
in LMIC, specifically for monitoring the safety of immunization in
pregnancy. Such capacity building could include the development
of specific training modules for data safety monitoring boards
(DSMBs) and National Immunization Technical Advisory Groups
(NITAGs). Investing in a globally concerted approach will give
added value to the individual studies/investments and strengthen
a multinational platform for immunization in pregnancy.
With increasing implementation of immunization in pregnancy
programs and research in LMIC, innovative approaches to validate
the implementation of classic research methods as well as novel
study designs and benefit-risk monitoring frameworks will be
needed as critical next elements of a global active safety monitor-
ing infrastructure, which will ultimately allow rapid evaluation
and response to safety signals or concerns related to products
and programs for maternal immunization.Conflict of interest disclosure
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